A Study of Enicepatide (CT-388) in Participants Who Are Overweight or Obese With Type 2 Diabetes Mellitus

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 447 participants.

Also called NCT06628362

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 447 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT06628362
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
United States, Argentina, Canada, Mexico, New Zealand, Puerto Rico (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT06628362. Randomized; double masking; primary purpose treatment. Start 2024-11-21 (actual); primary completion 2026-05-29 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study of Enicepatide (CT-388) in Participants Who Are Overweight or Obese With Type 2 Diabetes Mellitus
Condition
Overweight or Obese
Condition
Type 2 Diabetes Mellitus (T2DM)
Intervention (Drug)
Placebo
Intervention (Drug)
Enicepatide
Lead sponsor
Carmot Therapeutics, Inc. (class: industry)
Collaborator
Hoffmann-La Roche (class: industry)

Record details

Record id
cardio:ct-nct06628362
Content hash
0ace7b82133b92940b103adf4c826c57a66d866370fa5e482d0c06d5aafbc3ca